A phase II trial of post‑operative chemoradiotherapy for completely resected gastric cancer with D2 lymphadenectomy

Zhai,Yu‑Jie; Su,Yi‑Peng; Wang,Sheng‑Jie; Ning,Fang‑Ling; Wang,Zhen‑Bo; Yu,Wen‑Zheng; Chen,Shao‑Shui

doi:10.3892/ol.2014.2382

A phase II trial of post‑operative chemoradiotherapy for completely resected gastric cancer with D2 lymphadenectomy

Authors:
- Yu‑Jie Zhai
- Yi‑Peng Su
- Sheng‑Jie Wang
- Fang‑Ling Ning
- Zhen‑Bo Wang
- Wen‑Zheng Yu
- Shao‑Shui Chen
View Affiliations

Affiliations: Binzhou Medical University, Binzhou, Shandong, P.R. China , Department of Oncology, Affiliated Hospital of Binzhou Medical University, Binzhou, Shandong, P.R. China, Department of Hematology, Affiliated Hospital of Binzhou Medical University, Binzhou, Shandong, P.R. China
Published online on: July 25, 2014 https://doi.org/10.3892/ol.2014.2382
Pages: 1844-1848

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The optimal post‑operative adjuvant treatment for completely resected gastric cancer with D2 lymphadenectomy remains controversial. The present study was a phase II trial on post‑operative chemoradiotherapy in 30 patients with gastric cancer. Patients with stage II to IV (M0) gastric cancer received two cycles of chemotherapy prior to and following chemoradiotherapy. The chemotherapy consisted of a 2‑h infusion of oxaliplatin (100 mg/m2) and folinic acid (100 mg/m2), which was followed by a 46‑h continuous infusion of 5‑fluorouracil (5‑FU; 2,400 mg/m2) through a portable pump, repeated every 3 weeks. The chemoradiotherapy consisted of 45 Gy of radiotherapy for 5 weeks and 5‑FU continuous infusion (350 mg/m2/day). In total, 30 patients were enrolled in this study. All patients underwent the chemoradiotherapy treatment as planned. A total of 10 (33.3%) patients relapsed; two (6.7%) locoregional relapses and mediastinum metastases, four (13.3%) peritoneal relapses, and four (13.3%) distant metastases. The three‑year overall survival and disease‑free survival rates were 72.7 and 65%, respectively. The toxicities of chemotherapy and radiotherapy, consisting of neutropenia, nausea and hand‑foot syndrome, were observed. In conclusion, post‑operative chemoradiotherapy following complete resection of gastric cancer with D2 lymphadenectomy is feasible in a significant subset of patients.

View Figures

View References

1	Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011.
2	Park SH, Kim DY, Heo JS, et al: Postoperative chemoradiotherapy for gastric cancer. Ann Oncol. 14:1373–1377. 2003.
3	GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group. Paoletti X, Oba K, Burzykowski T, et al: Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA. 303:1729–1737. 2010.
4	Macdonald JS, Smalley SR, Benedetti J, et al: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 345:725–730. 2001.
5	Smalley SR, Benedetti JK, Haller DG, et al: Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol. 30:2327–2333. 2012.
6	Sasako M, Inoue M, Lin JT, et al: Gastric Cancer Working Group report. Jpn J Clin Oncol. 40(Suppl 1): i28–i37. 2010.
7	Kappas AM, Fatouros M and Roukos DH: Is it time to change surgical strategy for gastric cancer in the United States? Ann Surg Oncol. 11:727–730. 2004.
8	Songun I, Putter H, Kranenbarg EM, Sasako M and van de Velde CJ: Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 11:439–449. 2010.
9	Degiuli M, Sasako M and Ponti A; Italian Gastric Cancer Study Group. Morbidity and mortality in the Italian Gastric Cancer Study Group randomized clinical trial of D1 versus D2 resection for gastric cancer. Br J Surg. 97:643–649. 2010.
10	Wu CW, Hsiung CA, Lo SS, et al: Nodal dissection for patients with gastric cancer: a randomized controlled trial. Lancet Oncol. 7:309–315. 2006.
11	Oh DY and Bang YJ: Adjuvant and neoadjuvant therapy for gastric cancer. Curr Treat Options Oncol. 14:311–320. 2013.
12	Mullaney PJ, Wadley MS, Hyde C, Wyatt J, et al: Appraisal of compliance with the UICC/AJCC staging system in the staging of gastric cancer. Union Internacional Contra la Cancrum/American Joint Committee on Cancer. Br J Surg. 89:1405–1408. 2002.
13	Japanese Gastric Cancer Association. Japanese Classification of Gastric Carcinoma - 2nd English edition. Gastric Cancer. 1:10–24. 1998.
14	Ajani JA, Welch SR, Raber MN, Fields WS and Krakoff IH: Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest. 8:147–159. 1990.
15	Vasilescu C, Popa M, Tudor S, Manuc M and Diculescu M: Robotic surgery of locally advanced gastric cancer - an initial experience. Acta Chir Belg. 112:209–212. 2012.
16	Cunningham D, Allum WH, Stenning SP, et al; MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 355:11–20. 2006.
17	Nakashima S, Hatanaka N, Yoshikawa Y, et al: Long-term survival of a case of advanced cancer of the esophagogastric junction with complete response to low-dose 5-fluorouracil and cisplatin chemotherapy. Gan To Kagaku Ryoho. 39:1559–1561. 2012.(In Japanese).
18	Gomceli I, Demiriz B and Tez M: Gastric carcinogenesis. World J Gastroenterol. 18:5164–5170. 2012.
19	Hallissey MT, Dunn JA, Ward LC and Allum WH: The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: five-year follow-up. Lancet. 343:1309–1312. 1994.
20	Roviello F, Marrelli D, Morgagni P, et al; Italian Research Group for Gastric Cancer. Survival benefit of extended D2 lymphadenectomy in gastric cancer with involvement of second level lymph nodes: a longitudinalmulticenter study. Ann Surg Oncol. 9:894–900. 2002.
21	Lim DH, Kim DY, Kang MK, et al: Patterns of failure in gastric carcinoma after D2 gastrectomy and chemoradiotherapy: a radiation oncologist’s view. Br J Cancer. 91:11–17. 2004.
22	Leong CN, Chung HT, Lee KM, et al: Outcomes of adjuvant chemoradiotherapy after a radical gastrectomy and a D2 node dissection for gastric adenocarcinoma. Cancer J. 14:269–275. 2008.
23	Song S, Chie EK, Kim K, et al: Postoperative chemoradiotherapy in high risk locally advanced gastric cancer. Radiat Oncol J. 30:213–217. 2012.
24	Lee J, Lim do H, Kim S, et al: Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol. 30:268–273. 2012.